Regeneron Reports First Quarter 2026 Financial and Operating Results [Yahoo! Finance]
Regeneron Pharmaceuticals, Inc. (REGN)
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.regeneron.com
Company Research
Source: Yahoo! Finance
Dupixent ® global net sales (recorded by Sanofi) increased 33% to $4.9 billion EYLEA HD ® U.S. net sales increased 52% to $468 million; total EYLEA HD and EYLEA ® U.S. net sales decreased 10% to $941 million GAAP EPS of $6.75, including $0.82 negative impact from IPR&D; non-GAAP EPS (a) of $9.47, including $0.80 negative impact from IPR&D EYLEA HD approved by FDA as first and only injectable anti-VEGF with dosing intervals up to 5 months for wet age-related macular degeneration (wAMD) and diabetic macular edema (DME) Dupixent approved by FDA and European Commission (EC) for young children with chronic spontaneous urticaria (CSU); also approved by FDA as first and only medicine for allergic fungal rhinosinusitis (AFRS) Otarmeni ™ (lunsotogene parvec) approved by FDA as first and only gene therapy for genetic hearing loss; Regeneron to provide Otarmeni for free in U.S. New $3.0 billion share repurchase program authorized TARRYTOWN, N.Y., April 29, 2026 (GLOBE NEWSWIRE) --
Show less
Read more
Impact Snapshot
Event Time:
REGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
REGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
REGN alerts
High impacting Regeneron Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
REGN
News
- Regeneron Pharmaceuticals Q1 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
- Regeneron's C5 Milestones And Autoimmune Bets Shape Future Valuation [Yahoo! Finance]Yahoo! Finance
- Regeneron (NASDAQ:REGN) Reports Strong Q1 CY2026 [Yahoo! Finance]Yahoo! Finance
- Regeneron Reports First Quarter 2026 Financial and Operating ResultsGlobeNewswire
- Appian Celebrates 2026 Innovation Award Winners [TheStreet.com]TheStreet.com
REGN
Earnings
- 4/29/26 - Beat
REGN
Sec Filings
- 4/29/26 - Form 10-Q
- 4/29/26 - Form 8-K
- 4/24/26 - Form ARS
- REGN's page on the SEC website